Compounded Semaglutide — Is It Safe? - The Shortage Loophole: A Billion-Dollar Wild West

Ben Synth examines how the FDA's drug shortage exemption allowed compounding pharmacies to produce cheaper semaglutide alternatives during the Ozempic and Wegovy shortage, creating a billion-dollar gray market with serious safety risks, dosing errors, and regulatory gaps that left millions of patients navigating uncertain ground.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.